| Subject: | Lustgarten Foundation for Pancreatic Research |
Letter of Intent Date: August 3, 2007 (5:00 PM ET)
Application Deadline: August 20, 2007
The goal of this initiative is to make rapid advances in the battle against pancreatic cancer through a combination of cutting edge technology and novel ideas. Grants must focus on adenocarcinoma of the pancreas. Applications will be accepted from individual investigators as well as collaborating investigators
Priority will be given to grants focusing on the following areas:
Pancreatic cancer "stem cells," better known as tumor initiating cells. Particularly 1) epigenetic and genetic comparisons of the pancreatic cancer stem cell and non-stem cell compartments, 2) novel therapeutic approaches to target pancreatic cancer stem cells, and 3) clinical correlates of pancreatic stem cells, such as determining whether or not circulating cancer stem cells correlate with metastases, recurrence or survival.
Familial pancreatic cancer. Since a growing body of evidence now makes it clear that the clustering of pancreatic cancer in some families has a genetic basis, grant applications focusing on the study of familial pancreatic cancer will be given priority. These might include, but are not limited to, studies to characterize the patterns of clustering of pancreatic and non-pancreatic cancer, and novel approaches to find the "familial pancreatic cancer gene."
All other grants should fall in to the following categories:
Screening for the early detection of pancreatic cancer.
Screening can include the study of biospecimens and/or imaging.
Novel therapies in pancreatic cancer
Novel therapy applications should include the translation and application to human pancreatic cancer.
Novel technologies for pancreatic cancer genetics
Novel technologies for pancreatic cancer genetics applications can include animal models or
the study of human pancreatic cancer. If the proposal is based on the study of human
pancreatic cancer, the applicant should have experience purifying the neoplastic cells from
bulk pancreatic cancers, and should be able to demonstrate the ability to obtain the neoplastic cellularity needed to study the genetic alterations present in the cancers.
Grants will be awarded for a one-year period for a maximum amount of $100,000, of which no more than 10% can be used for indirect costs.
|
Please refer to the website for additional information or you can contact me at 3-4094. Thank you. |
Lynn Baldwin-Harrison
U. T. M.D. Anderson Cancer Center
Development Office - Faculty Grants Program - Unit 705
6900 Fannin, Suite 7.1000a
Houston, Texas 77030
713-563-4094
Posted: 30 Jul 2007 01:28 PM
Originally Posted: 30 Jul 2007 01:24 PM |
| 
